Evidence map›Paper›PMID 40066817›Full record

ArticleAnalytical chemistry2025

Streamlined High-Throughput Data Analysis Workflow for Antibody-Drug Conjugate Biotransformation Characterization.

Kate Liu, Yongling Ai, Hui Yin Tan, Jiaqi Yuan, John K Meissen, Yuzhuo Zhang, Yue Huang, Anton I Rosenbaum

Abstract read
In one paragraph

Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kate LiuIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.
Yongling AiIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.
Hui Yin TanIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.ORCID 0000-0001-9400-566X
Jiaqi YuanIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.ORCID 0000-0003-4575-452X
John K MeissenIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.
Yuzhuo ZhangSCIEX, 1201 Radio Rd., Redwood City, California 94065, United States.ORCID 0000-0003-1146-6474
Yue HuangIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.ORCID 0000-0003-2788-0856
Anton I RosenbaumIntegrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, California 94080, United States.ORCID 0000-0003-1939-951X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research into antibody-drug conjugates (ADCs) is currently at an inflection point due to recent clinical impact. ADC biotransformation analysis is key for understanding the structural integrity of ADCs in vivo and is a critical aspect of drug development, especially at the lead selection stage. Data analysis of biotansformed products is hindered by the manual and time-consuming analyte identification process oftentimes taking days to weeks. We developed a streamlined data analysis workflow enabling more automated peak identification using several commercial software tools that significantly improve data processing efficiency. A linker-payload biotransformation library was created for each new molecule and combined with antibody sequence information for peak matching. As a proof of concept, we tested this workflow across different payload and linker types, acquired using different mass spectrometers: an example using a topoisomerase I inhibitor-conjugated ADC (SCIEX ZenoTOF 7600) and a comparison to a published in vivo ADC biotransformation data set for a pyrrolobenzodiazepine-conjugated ADC (ThermoFisher QE HF-X). Using this more automated workflow, we rapidly identified major biotransformation species that were previously found manually including loss of linker-payload, thiosuccinimide ring hydrolysis, cysteinylation at the deconjugation site(s), and partial linker-payload cleavage. This improved data-analysis workflow has demonstrated superb effectiveness in streamlining overall ADC biotransformation identification and enabled quantification that was highly comparable to previously obtained results. Broadening application of advanced analytical techniques to study biotherapeutic biotransformation can now more effectively impact drug development by enabling faster design-test-analyze cycle times, critical in early drug discovery settings, opening new avenues for more effective collaboration between analytical chemists and bioconjugate engineers.

Indexed as

High-Throughput Screening AssaysImmunoconjugatesBiotransformationData AnalysisHumansWorkflowImmunoconjugates

Identifiers

PMID40066817
PMCPMC11948178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.